Compare Stocks: PPBT, LABT, SNGX, and CLGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLGN CollPlant Biotechnologies	$3.55	$3.32	$2.64 ▼ $31.80	N/A	1.79	1.03 million shs	236,429 shs
LABT Lakewood-Amedex Biotherapeutics	$1.88	$2.36	$1.66 ▼ $98.20	$4.45M	N/A	1.01 million shs	90,156 shs
PPBT Purple Biotech	$1.75	$1.56	$1.16 ▼ $14.10	$1.63M	0.71	3.98 million shs	340,923 shs
SNGX Soligenix	$0.38	$0.38	$0.28 ▼ $3.07	$5.63M	1.92	235,722 shs	108,826 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLGN CollPlant Biotechnologies	0.00%	-0.84%	+4.78%	-4.05%	-87.36%
LABT Lakewood-Amedex Biotherapeutics	0.00%	-18.26%	-15.32%	-70.64%	+187,999,900.00%
PPBT Purple Biotech	0.00%	+4.17%	+22.38%	-40.07%	-73.48%
SNGX Soligenix	0.00%	+0.85%	-3.09%	-10.06%	-86.71%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLGN CollPlant Biotechnologies	$3.55	$3.32	$2.64 ▼ $31.80	N/A	1.79	1.03 million shs	236,429 shs
LABT Lakewood-Amedex Biotherapeutics	$1.88	$2.36	$1.66 ▼ $98.20	$4.45M	N/A	1.01 million shs	90,156 shs
PPBT Purple Biotech	$1.75	$1.56	$1.16 ▼ $14.10	$1.63M	0.71	3.98 million shs	340,923 shs
SNGX Soligenix	$0.38	$0.38	$0.28 ▼ $3.07	$5.63M	1.92	235,722 shs	108,826 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLGN CollPlant Biotechnologies	0.00%	-0.84%	+4.78%	-4.05%	-87.36%
LABT Lakewood-Amedex Biotherapeutics	0.00%	-18.26%	-15.32%	-70.64%	+187,999,900.00%
PPBT Purple Biotech	0.00%	+4.17%	+22.38%	-40.07%	-73.48%
SNGX Soligenix	0.00%	+0.85%	-3.09%	-10.06%	-86.71%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLGN CollPlant Biotechnologies	1.50	Reduce	$120.00	3,280.28% Upside
LABT Lakewood-Amedex Biotherapeutics	1.00	Sell	N/A	N/A
PPBT Purple Biotech	2.00	Hold	$30.00	1,614.29% Upside
SNGX Soligenix	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest PPBT, LABT, SNGX, and CLGN Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/4/2026	CLGN CollPlant Biotechnologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/31/2026	PPBT Purple Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
8/17/2026	PPBT Purple Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
8/3/2026	PPBT Purple Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/20/2026	LABT Lakewood-Amedex Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (E-)
7/17/2026	SNGX Soligenix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/16/2026	PPBT Purple Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
6/26/2026	PPBT Purple Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
6/11/2026	PPBT Purple Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
6/8/2026	CLGN CollPlant Biotechnologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)

(Data available from 9/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLGN CollPlant Biotechnologies	$2.37M	2.16	N/A	N/A	$4.76 per share	0.75
LABT Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A	N/A	N/A	N/A
PPBT Purple Biotech	N/A	N/A	N/A	N/A	$10.39 per share	N/A
SNGX Soligenix	$120K	46.93	N/A	N/A	$0.52 per share	0.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLGN CollPlant Biotechnologies	-$11.49M	-$1.45	N/A	N/A	N/A	-683.68%	-218.81%	-139.28%	N/A
LABT Lakewood-Amedex Biotherapeutics	-$3.85M	-$4.75	N/A	1.42	N/A	N/A	N/A	N/A	N/A
PPBT Purple Biotech	-$26.39M	-$23.25	N/A	N/A	N/A	N/A	-147.77%	-111.59%	11/13/2026 (Estimated)
SNGX Soligenix	-$11.08M	-$0.98	N/A	N/A	N/A	N/A	-180.25%	-107.46%	11/6/2026 (Estimated)

Latest PPBT, LABT, SNGX, and CLGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	LABT Lakewood-Amedex Biotherapeutics	N/A	-$2.75	N/A	-$2.75	N/A	N/A
8/7/2026	Q2 2026	PPBT Purple Biotech	-$0.98	$1.07	+$2.05	-$0.40	N/A	N/A
8/7/2026	Q2 2026	SNGX Soligenix	-$0.1550	-$0.12	+$0.0350	-$0.12	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLGN CollPlant Biotechnologies	N/A	N/A	N/A	N/A	N/A
LABT Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A	N/A	N/A
PPBT Purple Biotech	N/A	N/A	N/A	N/A	N/A
SNGX Soligenix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLGN CollPlant Biotechnologies	N/A	2.27	1.99
LABT Lakewood-Amedex Biotherapeutics	N/A	7.70	7.70
PPBT Purple Biotech	N/A	3.70	3.70
SNGX Soligenix	N/A	2.77	2.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLGN CollPlant Biotechnologies	21.69%
LABT Lakewood-Amedex Biotherapeutics	N/A
PPBT Purple Biotech	9.64%
SNGX Soligenix	3.60%

Insider Ownership

Company	Insider Ownership
CLGN CollPlant Biotechnologies	9.60%
LABT Lakewood-Amedex Biotherapeutics	5.35%
PPBT Purple Biotech	2.98%
SNGX Soligenix	1.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLGN CollPlant Biotechnologies	70	1.44 million	1.31 million	Optionable
LABT Lakewood-Amedex Biotherapeutics	5	2.37 million	2.24 million	N/A
PPBT Purple Biotech	20	930,000	901,000	Optionable
SNGX Soligenix	20	14.82 million	14.54 million	Not Optionable

PPBT, LABT, SNGX, and CLGN Headlines

Recent News About These Companies

SNGX: Applying for Vaccine Development Funding for Ebola Vaccine

August 12, 2026 | finance.yahoo.com

Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

August 7, 2026 | prnewswire.com

Soligenix Expands At-the-Market Equity Offering Capacity

June 26, 2026 | tipranks.com

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

June 8, 2026 | prnewswire.com

Soligenix Expands At-The-Market Equity Financing Capacity

May 28, 2026 | tipranks.com

SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month – Ebola Vaccine Optimism Fuels Retail Frenzy

May 27, 2026 | finance.yahoo.com

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

May 26, 2026 | prnewswire.com

SOLIGENIX, INC.: Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

May 8, 2026 | finanznachrichten.de

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

May 8, 2026 | prnewswire.com

SNGX stock slumps to record low after lymphoma trial fails – all eyes now on Behçet’s disease treatment

April 29, 2026 | msn.com

SNGX phase 3 trial halted on HyBryte

April 29, 2026 | msn.com

SOLIGENIX, INC.: Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte in Treatment of Cutaneous T-Cell Lymphoma

April 28, 2026 | finanznachrichten.de

SNGX phase 3 trial halted — HyBryte setback puts strategy in question

April 28, 2026 | msn.com

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

April 28, 2026 | prnewswire.com

Soligenix (SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach

April 23, 2026 | finance.yahoo.com

Soligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach

April 23, 2026 | usatoday.com

Soligenix (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status

April 20, 2026 | financial-news.co.uk

Soligenix (SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status

April 20, 2026 | finance.yahoo.com

Soligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results

April 17, 2026 | financial-news.co.uk

Soligenix (SNGX) Advances CTCL Research With Interim Analysis, Comparative Study Results

April 17, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPBT, LABT, SNGX, and CLGN Company Descriptions

CollPlant Biotechnologies NASDAQ:CLGN

$3.55 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.

Lakewood-Amedex Biotherapeutics NASDAQ:LABT

$1.88 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide. The rapid rise of resistant pathogens has rendered many existing antibiotics ineffective against these pathogens, increasing the risk of severe infections, prolonged hospital stays, and substantial economic burdens. Despite this urgent need, the development of new antibiotics has slowed, with most advancements occurring within existing drug classes, leaving these new compounds vulnerable to resistance mechanisms. Our product candidates consist of antimicrobials targeting acute and chronic infectious diseases, which are delivered locally to the site of infection. As of March 2026, we hold 68 issued and 36 pending patent applications for our products and technologies, with coverage in major pharmaceutical markets. We have successfully completed our first exploratory human clinical trials for our lead product, the broad-spectrum Bisphosphocin® (anti-bacterial) Nu-3, which is being developed for the topical treatment of mildly infected diabetic foot ulcers (iDFU). We plan to conduct an initial Phase 2a safety and dose response study, followed by a placebo-controlled Phase 2b dose comparative study to identify the optimal dose for Phase 3 trials and eventual commercialization. This study will also determine the most appropriate administration regimen for Nu-3 gel formation in mildly infected diabetic foot ulcers. Additionally, we are advancing early-stage pipeline compounds and are focused on further characterizing them to identify the best clinical indications for non-clinical and clinical evaluation. Advancement of any of our product candidates to the commercialization stage is completely dependent on the outcome of clinical studies that are reviewed and approved by the FDA or other comparable regulatory authorities. Headquartered in University Park, Florida, we were originally incorporated in Delaware on July 11, 2006, under the name Nu Pharmas, Inc. (“Nu Pharmas”). We initially focused on antisense RNA research and the contract manufacturing of oligonucleotides. On April 9, 2007, Nu Pharmas acquired substantially all the assets of Renaissance Nutraceuticals, Inc., a Delaware corporation, and subsequently changed its name to Amedex Therapeutics, Inc. (“Amedex Therapeutics”). On November 11, 2007, Amedex Therapeutics acquired substantially all the assets of Lakewood Pharmaceuticals, Inc., a Delaware corporation. On February 1, 2008, Amedex Therapeutics changed its name to Lakewood-Amedex Inc. On June 5, 2025, the Company changed its name to Lakewood-Amedex Biotherapeutics Inc. and redomiciled as a Nevada corporation. Our corporate address is in University Park, Florida.

Purple Biotech NASDAQ:PPBT

$1.75 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

Soligenix NASDAQ:SNGX

$0.38 0.00 (0.00%)

As of 09/4/2026 03:59 PM Eastern

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PPBT, LABT, SNGX, and CLGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PPBT, LABT, SNGX, and CLGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PPBT, LABT, SNGX, and CLGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPBT, LABT, SNGX, and CLGN Company Descriptions

CollPlant Biotechnologies NASDAQ:CLGN

Lakewood-Amedex Biotherapeutics NASDAQ:LABT

Purple Biotech NASDAQ:PPBT

Soligenix NASDAQ:SNGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PPBT, LABT, SNGX, and CLGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PPBT, LABT, SNGX, and CLGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PPBT, LABT, SNGX, and CLGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPBT, LABT, SNGX, and CLGN Company Descriptions

CollPlant Biotechnologies NASDAQ:CLGN

Lakewood-Amedex Biotherapeutics NASDAQ:LABT

Purple Biotech NASDAQ:PPBT

Soligenix NASDAQ:SNGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools